nach oben

Clinical Rheumatology

Erschienen in:

31.07.2022 | Review Article

Health disparities in systemic lupus erythematosus—a narrative review

verfasst von: Bilal Hasan, Alice Fike, Sarfaraz Hasni

Erschienen in: Clinical Rheumatology | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

To describe root causes of health disparities by reviewing studies on incidence and outcomes of systemic lupus erythematosus (SLE) related to ethnic, race, gender, or socioeconomic differences and to propose solutions.

Recent findings

SLE outcomes have steadily improved over the past 40 years but are not uniformly distributed across various racial and ethnic groups. Belonging to racial and ethnic minority has been cited as a risk factor for more severe disease and poor outcome in SLE. Population-based registries have demonstrated that Black patients with SLE have significantly lower life expectancy compared to White patients. Lower socioeconomic status has been shown to be one of the strongest predictors of progression to end stage renal disease in lupus nephritis. An association between patient experiences of racial discrimination, increased SLE activity, and damage has also been described. The lack of representation of marginalized communities in lupus clinical trials further perpetuates these disparities. To that end, the goal of a rheumatology workforce that resembles the patients it treats has emerged as one of many solutions to current shortfalls in care.

Summary

Disparities in SLE incidence, treatment, and outcomes have now been well established. The root causes of these disparities are multifactorial including genetic, epigenetic, and socioeconomic. The underrepresentation of marginalized communities in lupus clinical trials further worsen these disparities. Efforts have been made recently to address disparities in a more comprehensive manner, but systemic causes of disparities must be acknowledged and political will is required for a sustained positive change.

• Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12:605–620. https://doi.org/10.1038/nrrheum.2016.137CrossRefPubMed

Bernatsky S et al (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550–2557. https://doi.org/10.1002/art.21955CrossRefPubMed

• Demas KL, Costenbader KH (2009) Disparities in lupus care and outcomes. Curr Opin Rheumatol 21:102–109. https://doi.org/10.1097/BOR.0b013e328323daadCrossRefPubMedPubMedCentral

Izmirly PM et al (2021) Prevalence of systemic lupus erythematosus in the united states: estimates from a meta-analysis of the centers for disease control and Prevention National Lupus Registries. Arthritis Rheumatol 73:991–996. https://doi.org/10.1002/art.41632CrossRefPubMedPubMedCentral

Dall’Era M et al (2017) The incidence and prevalence of systemic lupus erythematosus in San Francisco County, California: the California Lupus Surveillance Project. Arthritis Rheumatol 69:1996–2005. https://doi.org/10.1002/art.40191CrossRefPubMed

Rees F et al (2016) The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis 75:136–141. https://doi.org/10.1136/annrheumdis-2014-206334CrossRefPubMed

Arnaud L et al (2014) Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev 13:1082–1089. https://doi.org/10.1016/j.autrev.2014.08.034CrossRefPubMed

Sun K et al (2021) Racial differences in patient-provider communication, patient self-efficacy, and their associations with systemic lupus erythematosus-related damage: a cross-sectional survey. J Rheumatol 48:1022–1028. https://doi.org/10.3899/jrheum.200682CrossRefPubMed

Golder V et al (2013) Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. Lupus 22:1425–1430. https://doi.org/10.1177/0961203313500547CrossRefPubMed

10.

Lim SS et al (2014) The incidence and prevalence of systemic lupus erythematosus, 2002–2004: The Georgia lupus registry. Arthritis and Rheumatology 66:357–368. https://doi.org/10.1002/art.38239CrossRefPubMed

11.

Alarcón GS et al (2001) Systemic lupus erythematosus in three ethnic groups: IX. Differences in damage accrual. Arthritis Rheum 44:2797–2806. https://doi.org/10.1002/1529-0131(200112)44:12%3c2797::AID-ART467%3e3.0.CO;2-9CrossRefPubMed

12.

Alarcón GS et al (2002) Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 11:95–101. https://doi.org/10.1191/0961203302lu155oaCrossRefPubMed

13.

Pons-Estel BA et al (2004) The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics.” Medicine (Baltimore) 83:1–17. https://doi.org/10.1097/01.md.0000104742.42401.e2CrossRef

14.

Mok CC, Lau CS (2003) Lupus in Hong Kong Chinese. Lupus 12:717–722. https://doi.org/10.1191/0961203303lu451xxCrossRefPubMed

15.

Maningding E et al (2020) Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: the california lupus surveillance project. Arthritis Care Res (Hoboken) 72:622–629. https://doi.org/10.1002/acr.23887CrossRef

16.

Lim SS et al (2019) Racial disparities in mortality associated with systemic lupus erythematosus - Fulton and DeKalb Counties, Georgia, 2002–2016. MMWR Morb Mortal Wkly Rep 68:419–422. https://doi.org/10.15585/mmwr.mm6818a4CrossRefPubMedPubMedCentral

17.

Gianfrancesco MA et al (2021) Mortality among minority populations with systemic lupus erythematosus, including Asian and Hispanic/Latino persons—California, 2007–2017. Morb Mortal Wkly Rep 70:236. https://doi.org/10.15585/mmwr.mm7007a2CrossRef

18.

Wadee S, Tikly M, Hopley M (2007) Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology 46:1487–1491. https://doi.org/10.1093/rheumatology/kem180CrossRefPubMed

19.

Yates I, et al (2020) Representation in clinical trials: a review on reaching underrepresented populations in research. Clin Res Retrieved from:https://acrpnet.org/2020/08/10/representation-in-clinical-trials-a-review-on-reaching-underrepresented-populationsin-research/

20.

FitzGerald C, Hurst S (2017) Implicit bias in healthcare professionals: a systematic review. BMC Med Ethics 18:19. https://doi.org/10.1186/s12910-017-0179-8CrossRefPubMedPubMedCentral

21.

• Lima K et al (2020) Factors associated with participation in rheumatic disease–related research among underrepresented populations: a qualitative systematic review. Arthritis Care Res 72:1481–1489. https://doi.org/10.1002/acr.24036CrossRef

22.

Falasinnu T et al (2018) The representation of gender and race/ethnic groups in randomized clinical trials of individuals with systemic lupus erythematosus. Curr Rheumatol Rep 20:20. https://doi.org/10.1007/s11926-018-0728-2CrossRefPubMedPubMedCentral

23.

Isenberg D et al (2010) Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 49:128–140. https://doi.org/10.1093/rheumatology/kep346CrossRef

24.

Furie R et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930. https://doi.org/10.1002/art.30613CrossRefPubMedPubMedCentral

25.

Barber MRW, Clarke AE (2017) Socioeconomic consequences of systemic lupus erythematosus. Curr Opin Rheumatol 29:480–485. https://doi.org/10.1097/bor.0000000000000416CrossRefPubMed

26.

Alarcón GSMGJ, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, Bastian HM, Friedman AW, Reveille JD (2001) Lupus in minority populations, nature versus nurture systemic lupus erythematosus in three ethnic groups IX Differences in damage accrual. Arthritis Rheum 44:2797–2806. https://doi.org/10.1002/art.20409CrossRefPubMed

27.

Nee R et al (2015) Survival disparity of African American versus non-African American patients with ESRD due to SLE. Am J Kidney Dis 66:630–637. https://doi.org/10.1053/j.ajkd.2015.04.011CrossRefPubMed

28.

Ward MM (2007) Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis. J Rheumatol 34:2024–2027PubMed

29.

Ward MM (2008) Socioeconomic Status and the Incidence of ESRD. Am J Kidney Dis 51:563–572. https://doi.org/10.1053/j.ajkd.2007.11.023CrossRefPubMed

30.

Yelin ETL, Bunde J, Yazdany J (2019) Poverty, neighborhoods, persistent stress, and systemic lupus erythematosus outcomes: a qualitative study of the patients’ perspective. Arthritis Care Res 71:398–405. https://doi.org/10.1002/acr.23599CrossRef

31.

Bruce INOKA, Farewell V, Hanly JG, Manzi S, Su L, Gladman DD, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Petri M, Steinsson K, Dooley MA, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Urowitz MB (2015) Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 74:1706–1713. https://doi.org/10.1136/annrheumdis-2013-205171CrossRefPubMed

32.

Chae DHMC, Fuller-Rowell TE, Spears EC, Smith TTG, Hunter EA, Drenkard C, Lim SS (2019) Racial discrimination, disease activity, and organ damage: the Black Women’s Experiences Living With Lupus (BeWELL) study. Am J Epidemiol 188:1434–1443. https://doi.org/10.1093/aje/kwz105CrossRefPubMedPubMedCentral

33.

Martz CDAA, Fuller-Rowell TE, Spears EC, Lim SS, Drenkard C, Chung K, Hunter EA, Chae DH (2019) Vicarious racism stress and disease activity: the Black Women’s Experiences Living with Lupus (BeWELL) Study. J Racial Ethn Health Disparities 6:1044–1051. https://doi.org/10.1007/s40615-019-00606-8CrossRefPubMedPubMedCentral

34.

Mirin AA (2021) Gender disparity in the funding of diseases by the U.S. National Institutes of Health. J Womens Health 30:956–963. https://doi.org/10.1089/jwh.2020.8682CrossRef

35.

Scofield RHBG, Namjou B, Kimberly RP, Ramsey-Goldman R, Petri M, Reveille JD, Alarcón GS, Vilá LM, Reid J, Harris B, Li S, Kelly JA, Harley JB (2008) Klinefelter’s syndrome (47, XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheumatol 58:2511–2517. https://doi.org/10.1002/art.23701CrossRef

36.

Gupta SNS, Blanco LP, O’Neil LJ, Wigerblad G, Goel RR, Mistry P, Jiang K, Carmona-Rivera C, Chan DW, Wang X, Pedersen HL, Gadkari M, Howe KN, Naz F, Dell’Orso S, Hasni SA, Dempsey C, Buscetta A, Frischmeyer-Guerrerio PA, Kruszka P, Muenke M, Franco LM, Sun HW, Kaplan MJ (2020) Sex differences in neutrophil biology modulate response to type I interferons and immunometabolism. Proc Natl Acad Sci USA 117:16481–16491. https://doi.org/10.1073/pnas.2003603117CrossRefPubMedPubMedCentral

37.

Yazdany J et al (2012) Quality of care in systemic lupus erythematosus: application of quality measures to understand gaps in care. J Gen Intern Med 27:1326–1333. https://doi.org/10.1007/s11606-012-2071-zCrossRefPubMedPubMedCentral

38.

Kaplowitz ET et al (2018) Contribution of socioeconomic status to racial/ethnic disparities in adverse pregnancy outcomes among women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 70:230–235. https://doi.org/10.1002/acr.23263CrossRef

39.

Jindal RMRJ, Sajjad I, Murthy MH, Baines LS (2005) Kidney transplantation and gender disparity. Am J Nephrol 25:474–483. https://doi.org/10.1159/000087920CrossRefPubMed

40.

Adams SVRM, Streja E, Cheung AK, Arah OA, Kalantar-Zadeh K, Mehrotra R (2017) Sex differences in hospitalizations with maintenance hemodialysis. J Am Soc Nephrol 28:2721–2728. https://doi.org/10.1001/archinte.160.15.2349CrossRefPubMedPubMedCentral

41.

Cooper GSWJ, Bernatsky S, Claudio JO, Clarke A, Rioux JD (2010) Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology 49:2172–2180. https://doi.org/10.1093/rheumatology/keq214CrossRefPubMedPubMedCentral

42.

Lanata CNR, Nitiham J, Taylor K, Barcellos L, Chung S, Criswell L (2015) Residential proximity to highways, DNA methylation and systemic lupus erythematosus. Arthritis Care Res 67:1604–1605

43.

Fernández M et al (2007) A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 57:576–584. https://doi.org/10.1002/art.22672CrossRefPubMed

44.

Vilá LM et al (2003) Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology 43:358–363. https://doi.org/10.1093/rheumatology/keh048CrossRefPubMed

45.

Yazdany JGJ, Trupin L, Katz P, Panopalis P, Criswell LA, Yelin E (2007) Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus. Arthritis Rheum 57:593–600. https://doi.org/10.1002/art.22674CrossRefPubMedPubMedCentral

46.

Feldman CHHL, Liu J, Fischer MA, Solomon DH, Alarcón GS, Winkelmayer WC, Costenbader KH (2013) Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum 65:753–763. https://doi.org/10.1002/art.37795CrossRefPubMedPubMedCentral

47.

Limou SNG, Kopp JB, Winkler CA (2014) APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis 21:426–433. https://doi.org/10.1053/j.ackd.2014.06.005CrossRefPubMedPubMedCentral

48.

Lanata CM NJ, Taylor KE, Chung SA, Torgerson DG, Seldin MF, Pons-Estel BA, Tusié-Luna T, Tsao BP, Morand EF, Alarcón-Riquelme ME, Criswell LA (2018) Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients. PLoS One 13:e0199003. https://doi.org/10.1371/journal.pone.0199003.

49.

Breitbach MERR, Roberts K, Kimberly RP, Absher D (2020) Population-specific patterns of epigenetic defects in the B cell lineage in patients with systemic lupus erythematosus. Arthritis Rheum 72:282–291. https://doi.org/10.1002/art.41083CrossRef

50.

Lanata CMPI, Nititham J, Taylor KE, Gianfrancesco M, Paranjpe M, Andrews S, Chung SA, Rhead B, Barcellos LF, Trupin L, Katz P, Dall’Era M, Yazdany J, Sirota M, Criswell LA (2019) A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nat Commun 10:1–13. https://doi.org/10.1038/s41467-019-11845-yCrossRef

51.

Feldman CHCK, Solomon DH, Subramanian SV, Kawachi I (2019) Area-level predictors of medication nonadherence among US medicaid beneficiaries with lupus: a multilevel study. Arthritis Care Res 71:903–913. https://doi.org/10.1002/acr.23721CrossRef

52.

Pons-Estel GJ et al (2012) The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort. Lupus 21:1397–1404. https://doi.org/10.1177/0961203312458465CrossRefPubMedPubMedCentral

53.

Yen EY et al (2017) 46-year trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: a nationwide population-based study. Ann Intern Med 167:777–785. https://doi.org/10.7326/m17-0102CrossRefPubMedPubMedCentral

54.

Canney MID, McCandless LC, Reich HN, Barbour SJ (2019) Disease-specific incident glomerulonephritis displays geographic clustering in under-serviced rural areas of British Columbia, Canada. Kidney Int 96:421–428. https://doi.org/10.1016/j.kint.2019.02.032CrossRefPubMed

55.

Popejoy ABFS (2016) Genomics is failing on diversity. Nature 538:161–164. https://doi.org/10.1038/538161aCrossRefPubMedPubMedCentral

56.

Sirugo GWS, Tishkoff SA (2019) The missing diversity in human genetic studies. Cell 177:26–31. https://doi.org/10.1016/j.cell.2019.02.048CrossRefPubMedPubMedCentral

57.

Lewandowski LB et al (2017) Missed opportunities for timely diagnosis of pediatric lupus in South Africa: a qualitative study. Pediatr Rheumatol 15:14. https://doi.org/10.1186/s12969-017-0144-6CrossRef

58.

Dey D et al (2021) Health disparities in rheumatic diseases: understanding global challenges in Africa, Europe, Latin America, and Asia and Proposing Strategies for Improvement. Rheum Dis Clin North Am 47:119–132. https://doi.org/10.1016/j.rdc.2020.09.009CrossRefPubMed

59.

Rubinstein TB et al (2018) Delays to care in pediatric lupus patients: data from the childhood arthritis and rheumatology research alliance legacy registry. Arthritis Care Res 70:420–427. https://doi.org/10.1002/acr.23285CrossRef

60.

Yazdany JMB, Dean ML, Bardach NS, Duseja R, Ward MM, Dudley RA (2014) Thirty-day hospital readmissions in systemic lupus erythematosus: predictors and hospital- and state-level variation. Arthritis Rheum 66:2828–2836. https://doi.org/10.1002/art.38768CrossRef

61.

Feldman CH et al (2020) Patterns and predictors of recurrent acute care use among Medicaid beneficiaries with systemic lupus erythematosus. Semin Arthritis Rheum 50:1428–1436. https://doi.org/10.1016/j.semarthrit.2020.02.012CrossRefPubMedPubMedCentral

62.

Nápoles AMS-OJ, Karliner LS, Gregorich SE, Pérez-Stable EJ (2015) Inaccurate language interpretation and its clinical significance in the medical encounters of Spanish-speaking Latinos. Med Care 53:940–947. https://doi.org/10.1097/MLR.0000000000000422CrossRefPubMedPubMedCentral

63.

Sudore RLLC, Pérez-Stable EJ, Bibbins-Domingo K, Williams BA, Schillinger D (2009) Unraveling the relationship between literacy, language proficiency, and patient-physician communication. Patient Educ Couns 75:398–402. https://doi.org/10.1016/j.pec.2009.02.019CrossRefPubMedPubMedCentral

64.

Wu XYYM, Xie YS, Xiao WG, Lin J, Zhou B, Guan X, Luo CN, Che N, Liu XZ, Wang C, Teng JL, Cheng XB, Ye JN, Su YT, Shi H, Yin YF, Liu MR, Sun Y, Hu QY, Zhou ZC, Chi HH, Liu Y, Zhang X, Chen JW, Zhang MJ, Zhao DB, Yang CD, Wu LJ, Liu HL (2019) Causes of death in hospitalized patients with systemic lupus erythematosus: a 10-year multicenter nationwide Chinese cohort. Clin Rheumatol 38:107–115. https://doi.org/10.1007/s10067-018-4259-zCrossRefPubMed

65.

Bultink IEM, de Vreis F, van Vollenhoven RF, Lalmohamed A (2021) Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology 60:207–216. https://doi.org/10.1093/rheumatology/keaa267CrossRefPubMed

66.

Falasinnu T et al (2019) Unraveling race, socioeconomic factors, and geographical context in the heterogeneity of lupus mortality in the United States. ACR Open Rheumatol 1:164–172. https://doi.org/10.1002/acr2.1024CrossRefPubMedPubMedCentral

67.

Hiraki LTFC, Marty FM, Winkelmayer WC, Guan H, Costenbader KH (2017) Serious infection rates among children with systemic lupus erythematosus enrolled in medicaid. Arthritis Care Res 69:1620–1626. https://doi.org/10.1002/acr.23219CrossRef

68.

Sun KEA, Criscione-Schreiber LG, Sadun RE, Rogers JL, Doss J, Corneli AL, Bosworth HB, Clowse MEB (2020) Racial Disparities in medication adherence between African American and Caucasian patients with systemic lupus erythematosus and their associated factors. ACR Open Rheumatol 2:430–437. https://doi.org/10.1002/acr2.11160CrossRefPubMedPubMedCentral

69.

Shen MJ et al (2018) The effects of race and racial concordance on patient-physician communication: a systematic review of the literature. J Racial Ethn Health Disparities 5:117–140. https://doi.org/10.1007/s40615-017-0350-4CrossRefPubMed

70.

Feldman CHCJ, Zhang Z, Subramanian SV, Solomon DH, Kawachi I, Costenbader KH (2018) Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. Semin Arthr Rheum 48:205–213. https://doi.org/10.1016/j.semarthrit.2018.01.002CrossRef

71.

Chehab GSG, Richter JG, Brinks R, Willers R, Fischer-Betz R, Winkler-Rohlfing B, Schneider M (2018) Medical adherence in patients with systemic lupus erythematosus in Germany: predictors and reasons for non-adherence - a cross-sectional analysis of the LuLa-cohort. Lupus 27:1652–1660. https://doi.org/10.1177/0961203318785245CrossRefPubMed

72.

Daleboudt GMBE, McQueen F, Kaptein AA (2011) Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus. Arthritis Care Res 63:342–350. https://doi.org/10.1002/acr.20411CrossRef

73.

Flower CHI, Campbell M (2016) The effect of psychosocial and neuropsychiatric factors on medication adherence in a cohort of women with systemic lupus erythematosus. J Clin Rheumatol 22:411–417. https://doi.org/10.1097/RHU.0000000000000470CrossRefPubMed

74.

Shenavandeh SMA, Eazadnegahdar M, Nekooeian A (2021) Medication adherence of patients with systemic lupus erythematosus and rheumatoid arthritis considering the psychosocial factors, health literacy and current life concerns of patients. Curr Rheumatol Rev 17:412–420. https://doi.org/10.2174/1573397117666210301144651CrossRefPubMed

75.

Mosley-Williams ALM, Gillis M, Leisen J, Guice D (2002) Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum 47:630–638. https://doi.org/10.1002/art.10790CrossRefPubMed

76.

Du XCH, Zhuang Y, Zhao Q, Shen B (2020) Medication adherence in Chinese patients with systemic lupus erythematosus. J Clin Rheumatol 26:94–98. https://doi.org/10.1097/RHU.0000000000000952CrossRefPubMed

77.

Zheng YYD, Pan HF, Li WX, Li LH, Li J, Li XP, Xu JH (2009) Influence of social support on health-related quality of life in patients with systemic lupus erythematosus. Clin Rheumatol 28:265–269. https://doi.org/10.1007/s10067-008-1033-7CrossRefPubMed

78.

Zamora-Racaza GAD, Ishimori ML, Ormseth SR, Wallace DJ, Penserga EG, Sumner L, Ayeroff J, Draper T, Nicassio PM, Weisman MH (2018) Role of psychosocial reserve capacity in anxiety and depression in patients with systemic lupus erythematosus. Int J Rheum Dis 21:850–858. https://doi.org/10.1111/1756-185X.13033CrossRefPubMed

79.

Berkman NDSS, Donahue KE, Halpern DJ, Crotty K (2011) Low health literacy and health outcomes: an updated systematic review. Ann Intern Med 155:97–107. https://doi.org/10.7326/0003-4819-155-2-201107190-00005CrossRefPubMed

80.

Maheswaranathan M et al (2021) Low health numeracy is associated with higher disease activity in systemic lupus erythematosus. Lupus 30:489–494. https://doi.org/10.1177/0961203320979044CrossRefPubMed

81.

Katz P et al (2021) Impact of limited health literacy on patient-reported outcomes in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 73:110–119. https://doi.org/10.1002/acr.24361CrossRef

82.

Kumar KGC, Toescu V, Buckley CD, Horne R, Nightingale PG, Raza K (2008) Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatology 47:690–697. https://doi.org/10.1093/rheumatology/ken050CrossRefPubMed

83.

Zhang L LW, Geng S, Ye S, Wang X, Qian L, Ding Y, Li T, Jiang A (2019) Lack of patient education is risk factor of disease flare in patients with systemic lupus erythematosus in China. BMC Health Serv Res 19:378. https://doi.org/10.1186/s12913-019-4206-y

84.

Hardy CGD, Su J, Rozenbojm N, Urowitz MB (2021) Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population. Rheumatol Intl 41:1457–1464. https://doi.org/10.1007/s00296-021-04898-0CrossRef

85.

Drenkard C et al (2020) Overcoming barriers to recruitment and retention of African-American women with SLE in behavioural interventions: lessons learnt from the WELL study. Lupus Sci Med 7:e000391. https://doi.org/10.1136/lupus-2020-000391CrossRef

86.

Heisler M, Piette JD (2005) “I help you, and you help me”: facilitated telephone peer support among patients with diabetes. Diabetes Educ 31:869–879. https://doi.org/10.1177/0145721705283247CrossRefPubMed

87.

Rotheram-Borus MJ et al (2014) A cluster randomized controlled trial evaluating the efficacy of peer mentors to support South African women living with HIV and their infants. PLoS ONE 9:e84867. https://doi.org/10.1371/journal.pone.0084867CrossRefPubMedPubMedCentral

88.

Williams EM et al (2019) Peer approaches to self-management (PALS): comparing a peer mentoring approach for disease self-management in African American women with lupus with a social support control: study protocol for a randomized controlled trial. Trials 20:529. https://doi.org/10.1186/s13063-019-3580-4CrossRefPubMedPubMedCentral

89.

Gross D et al (2016) Lupus education advancement project (LEAP): Rheumatology fellows serving as educators increased knowledge and efficiency in lupus recognition and referral by providers in primary and emergency care. Arthritis Rheumatol 68:2595–2596. https://doi.org/10.1002/art.39977CrossRef

90.

Bouye KE, McCleary KJ, Williams KB (2016) Increasing diversity in the health professions: reflections on student pipeline programs. J Healthc Sci Humanit 6:67–79PubMedPubMedCentral

91.

• Navarra SV, Zamora LD, Collante MTM (2020) Lupus education for physicians and patients in a resource-limited setting. Clin Rheumatol 39:697–702. https://doi.org/10.1007/s10067-019-04795-9CrossRefPubMed

92.

Heller C et al (2014) Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review. Contemp Clin Trials 39:169–182. https://doi.org/10.1016/j.cct.2014.08.004CrossRefPubMedPubMedCentral

93.

Schudrich W, Gross D, Rowshandel J (2012) Lupus and community-based social work. Soc Work Health Care 51:627–639. https://doi.org/10.1080/00981389.2012.683694CrossRefPubMed

94.

• McDougall J (2021) Leveraging telemedicine as an approach to address rheumatic disease health disparities. Rheum Dis Clin North Am 47:97–107. https://doi.org/10.1016/j.rdc.2020.09.008CrossRefPubMed

95.

Ritschl V et al (2021) Suitability for e-health of non-pharmacological interventions in connective tissue diseases: scoping review with a descriptive analysis. RMD Open 7:e001710. https://doi.org/10.1136/rmdopen-2021-001710CrossRefPubMedPubMedCentral

96.

Druce KL et al (2017) Recruitment and ongoing engagement in a UK smartphone study Examining the association between weather and pain: cohort study. JMIR Mhealth Uhealth 5:e168. https://doi.org/10.2196/mhealth.8162CrossRefPubMedPubMedCentral

97.

Bell K et al (2021) Patient-reported outcome information collected from lupus patients using a mobile application: compliance and validation. ACR Open Rheumatol 4:99–109. https://doi.org/10.1002/acr2.11370CrossRefPubMedPubMedCentral

Titel: Health disparities in systemic lupus erythematosus—a narrative review
verfasst von: Bilal Hasan
Alice Fike
Sarfaraz Hasni
Publikationsdatum: 31.07.2022
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 11/2022
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-022-06268-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2022

The skin as the first sign of a rare complication of rheumatoid arthritis

The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis

Intestinal pseudo-obstruction in systemic lupus erythematosus: an analysis of nationwide inpatient sample

Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients

Correction to: Impact of smoking habit on adult-onset Still’s disease prognosis, findings from a multicentre observational study